JPRN-UMIN000051192Not yet recruitingUnknown
Association of tenofovir disoproxil fumarate use with bone-related adverse events in chronic hepatitis B: a systematic review and meta-analysis - Association of tenofovir disoproxil fumarate use with bone-related adverse events in chronic hepatitis B: a systematic review and meta-analysis
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
- Hyogo Medical University
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Other
Eligibility Criteria
- Ages
- 18years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study Coinfection with HCV, HIV or HDV
Investigators
Similar Trials
Active, not recruiting
Phase 1
The effect of two related HIV-medicines (TDF and TAF) on small intestine gut wall - could that explain why TDF seems to decrease and TAF to increase body weightHIV-positive people who have good and stable treatment response for HIV-medication which includes either tenofovir disoproxil (TDF) or tenoforvir alafenamide (TAF)EUCTR2022-000849-32-FIHelsinki University Hospital24
Recruiting
Not Applicable
Efficacy and safety of tenofovir disoproxil fumarete (TDF) in nucleos(t)ide analogue-naive patients with hepatitis B virusPatients with chronic hepatitis B virus infectionJPRN-UMIN000017728Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology200
Active, not recruiting
Unknown
Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsEffectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsInfections and InfestationsISRCTN80908109GlaxoSmithKline (China) Investment Co., Ltd.2,000
Active, not recruiting
Phase 1
Efficacy of the Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine combination in people living with HIV with a history of M184V/I mutation and virologically controlled: a phase II, open-label, non-comparative pilot study.Patients living with HIV-1 who are virologically controlled and carry an M184V/I mutation in a previous genotypeMedDRA version: 20.1Level: LLTClassification code: 10020160Term: HIV disease Class: 10021881CTIS2023-505845-17-00Centre Hospitalier Universitaire De Caen Normandie32
Unknown
Phase 2
Pharmacology of Tenofovir Disoproxil Fumarate-Emtricitabine (TDF-FTC) Pre-exposure Prophylaxis in Kenyan Cisgender WomeHIV/AIDSPACTR202311518894272niversity of Washington72